文献速递前列腺癌

中危前列腺癌的主动监测:系统综述、Meta分析与Meta回归

Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and Metaregression.
PubMed 文献 · Eur Urol Oncol · 2022-08-04

本系统综述与Meta分析纳入25项研究共29673例未经选择的中危前列腺癌患者,评估主动监测下的无治疗生存与肿瘤学结局。中危患者无治疗生存与低危患者相似(RR 1.16,95%CI 0.99-1.36,p=0.07),但转移(RR 5.79)、前列腺癌死亡(RR 3.93)和全因死亡(RR 1.44)风险显著更高。仅纳入GG≤2患者的亚组分析中,无治疗生存与无转移生存与低危患者相似。

要点

  • 未经选择的中危患者主动监测下转移和前列腺癌死亡风险显著高于低危患者。
  • 中危与低危患者无治疗生存相似(RR 1.16,95%CI 0.99-1.36,p=0.07)。
  • 仅纳入GG≤2患者的亚组中,无治疗生存与无转移生存与低危相似。

核心结论

  • 本系统综述与Meta分析强调需要优化中危特征患者的选择。
  • 研究结果支持将主动监测的中危患者限定为低体积GG 2肿瘤者。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed/Medline、Embase和Web of Science数据库至2022年2月。
  • 遵循PRISMA指南识别合格研究,共纳入25项研究、29673例未经选择的中危前列腺癌患者。
  • 共同主要结局为无治疗生存、无转移生存、癌症特异性生存和总生存。
  • 预先计划亚组分析,探讨仅纳入Gleason分级(GG)≤2的中危患者时主动监测的结局。

主要发现

  • 10年无治疗生存、无转移生存、癌症特异性生存和总生存范围分别为19.4%-69%、80.8%-99%、88.2%-99%和59.4%-83.9%。
  • 中危患者无治疗生存与低危患者相似(RR 1.16,95%CI 0.99-1.36,p=0.07)。
  • 中危患者转移风险显著高于低危患者(RR 5.79,95%CI 4.61-7.29,p<0.001)。
  • 中危患者前列腺癌死亡风险显著高于低危患者(RR 3.93,95%CI 2.93-5.27,p<0.001)。
  • 中危患者全因死亡风险显著高于低危患者(RR 1.44,95%CI 1.11-1.86,p=0.005)。

关键数值与推荐

  • 仅纳入GG≤2患者的亚组分析(n=4)中,中危与低危患者无治疗生存相似(RR 1.03,95%CI 0.62-1.71,p=0.91)。
  • 仅纳入GG≤2患者的亚组分析(n=4)中,中危与低危患者无转移生存相似(RR 2.09,95%CI 0.75-5.82,p=0.16)。
  • 不利中危疾病和活检癌症长度增加亚组中无治疗生存显著降低。

临床怎么用

  • 作者认为研究结果支持将主动监测的中危患者限定为低体积GG 2肿瘤者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Active surveillance (AS) is increasingly selected among patients with localized, intermediate-risk (IR) prostate cancer (PCa). However, the safety and optimal candidate selection for those with IR PCa remain uncertain. OBJECTIVE: To evaluate treatment-free survival and oncologic outcomes in patients with IR PCa managed with AS and to compare with AS outcomes in low-risk (LR) PCa patients. EVIDENCE ACQUISITION: A literature search was conducted through February 2022 using PubMed/Medline, Embase, and Web of Science databases. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed to identify eligible studies. The coprimary outcomes were treatment-free, metastasis-free, cancer-specific, and overall survival. A subgroup analysis was planned a priori to explore AS outcomes when limiting inclusion to IR patients with a Gleason grade (GG) of ≤2. EVIDENCE SYNTHESIS: A total of 25 studies including 29 673 unselected IR patients met our inclusion criteria. The 10-yr treatment-free, metastasis-free, cancer-specific, and overall survival ranged from 19.4% to 69%, 80.8% to 99%, 88.2% to 99%, and 59.4% to 83.9%, respectively. IR patients had similar treatment-free survival to LR patients (risk ratio [RR] 1.16, 95% confidence interval (CI), 0.99-1.36, p = 0.07), but significantly higher risks of metastasis (RR 5.79, 95% CI, 4.61-7.29, p < 0.001), death from PCa (RR 3.93, 95% CI, 2.93-5.27, p < 0.001), and all-cause death (RR 1.44, 95% CI, 1.11-1.86, p = 0.005). In a subgroup analysis of studies including patients with GG ≤2 only (n = 4), treatment-free survival (RR 1.03, 95% CI, 0.62-1.71, p = 0.91) and metastasis-free survival (RR 2.09, 95% CI, 0.75-5.82, p = 0.16) were similar between LR and IR patients. Treatment-free survival was significantly reduced in subgroups of patients with unfavorable IR disease and increased cancer length on biopsy. CONCLUSIONS: The present systematic review and meta-analysis highlight the need to optimize patient selection for those with IR features. Our findings support limiting the inclusion of IR patients in AS to those with low-volume GG 2 tumor. PATIENT SUMMARY: Active surveillance is increasingly used in patients with localized, intermediate-risk (IR) prostate cancer. In this population, we have reported higher risks of metastasis and cancer mortality in unselected patients than in patients with low-risk features, underscoring the need to optimize the selection of patients with IR features.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Baboudjian M, Breda A, Rajwa P, et al. Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and Metaregression. Eur Urol Oncol. 2022. PMID: 35934625. doi:10.1016/j.euo.2022.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。